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ABSTRACT 
Objective: To formulate and evaluate propranolol hydrochloride topical gel for overcoming the limitations and low oral bioavailability associated 
with conventional therapy. 
Methods: The propranolol hydrochloride topical gels were prepared by the cold mechanical method. The preliminary evaluation and further 
characterisation studies was conducted to find the optimised formulation. The in vitro release and ex vivo permeation studies were investigated. The 
histopathological studies and stability studies was also assessed. 
Results: The propranolol hydrochloride topical gel was successfully prepared. The in vitro release of optimized topical propranolol hydrochloride gel 
formulation (G2) showed the highest cumulative percentage drug release that is, 95.55%±0.15 after 7.5 h. (G2) the formulation showed a higher flux 
value of 4.61μg/cm2/h. The histopathological study using pig skin revealed that the optimized formulation was found to be safe for topical application. 
Conclusion: The formulated topical gel containing propranolol Hydrochloride seems to be a promising dosage form for enhanced skin delivery of 
propranolol hydrochloride in treating Infantile Hemangioma. 
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INTRODUCTION 
Infantile Hemangioma (IH) is benign vascular tumors or soft tissue 
tumors of childhood, characterized by endothelial cell proliferation. 
It is usually referred as “Strawberry Hemangiomas” because it 
appears as a red or blue raised lesion [1]. The prevalence of Infantile 
Hemangioma is about 1-10% across the world population and it is 
more frequently occur in low birth weight, female, premature infants 
and in twin birth. The tumours are commonly developed during 
infancy and only about 20% of them being present at birth. The main 
complications associated with Infantile Hemangiomas include risk of 
bleeding, tissue damage, ulceration, infection, pain, functional 
impairment, disfigurement of tissues etc. [2]. Congenital structural 
abnormalities are associated with some types of IH. IH are classified 
on the basis of morphological features into superficial, deep and 
mixed types [3]. Superficial hemangiomas are identified by bright 
red vascular nodules and plaques [4]. Deep hemangiomas are 
commonly characterized by subcutaneous, bluish vascular swellings 
and compressible lesions. Mixed hemangiomas are the combinations 
of both superficial and deep hemangiomas. Based on the 
distributions, IH are classified as localized, segmental, indeterminate 
and multifocal hemangiomas [5]. Vasculogenesis and angiogenesis 
are the important mechanisms underlying the pathophysiology of 
Infantile Hemangioma. Equilibrium between proangiogenic and 
angiogenic factors are disturbed by hypoxia and acidosis and result 
in endothelial proliferation, thus increases the growth rate of 
lesions. In addition to the proliferation of endothelial cells, acidosis 
and perinatal hypoxia increases the secretion of vascular endothelial 
growth factor (VEGF) by stimulating angiogenesis [6]. The 
angiogenic factors H1F1-alpha plays an important role in the 
induction of gene transcription of VEGF. Several theories are 
illustrated to give a brief idea about the pathogenesis of IH, including 
the placental hypothesis, vasculogenesis theory and hormonal 
theory [7]. The treatment options included in the current treatment 
strategy of Infantile Hemangioma includes the use of systemic or 
topical beta-blockers, systemic or intralesional corticosteroids, 
Interferons, pulsed dye laser therapy, surgical excision etc. The first 
line agent that is preferred in the treatment of Infantile Hemangioma 
is propranolol hydrochloride because of its rapid onset of action and 
good drug tolerability [8]. The orally and intralesionally available 
therapies are associated with various types of adverse effects, so it is 
necessary to develop a topical formulation to treat this disease 
condition. Various advancements in the novel drug delivery system 
provide a wide opportunity for these limitations. Formulation of 
topical gels by using the first-line agent like propranolol hydrochloride 
is considered as efficient for the treatment of Infantile Hemangioma. 
Gels are more advantageous when compared to other topical 
formulations because of its easy application and increased patient 
compliance. The usage of polymers such as Carbapol 934 and HPMC in 
the formulation of gels can improve drug permeation and drug release 
properties of gels. The transdermal route of drug administration 
provides systemic delivery of drugs by applying the drug to unbroken 
and healthy skin, thus ensuring a sustained release of drugs and 
bypasses the Hepatic first-pass metabolism. Transdermal delivery of 
drugs significantly delivers an appropriate amount of drugs, thus 
overcoming conventional problems of oral dosing [9]. Hence the 
current study aims to formulate and evaluate topical gel containing 
propranolol hydrochloride for treating Infantile Hemangioma. 
MATERIALS AND METHODS 
Materials and excipients 
The drug of choice, propranolol hydrochloride, was provided by 
Research fine chemicals Industries, Mumbai. Other ingredients used 
in this study were of standard grade. 
Preformulation studies 
Fourier transform infrared (FTIR) spectroscopy  
The FTIR spectra of drug and excipients were obtained to ascertain 
the compatibility between propranolol hydrochloride and selected 
polymers using FTIR spectrophotometer by Potassium Bromide 
(KBr) pressed pellet method [10]. 
Solubility studies 
Solubility profile of the drug was performed in various solvents such 
as chloroform, propylene glycol, distilled water, methanol, acetone 
and Phosphate Buffer Saline (PBS) pH 5.8 [11]. 
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Melting point of the drug 
Open capillary tube method was used to determine the melting point 
[12]. 
Lambda max of propranolol hydrochloride in phosphate buffer 
solution (PBS) pH 5.8 
Absorption maxima of propranolol hydrochloride were determined 
in PBS pH 5.8 [13]. Standard stock solution was prepared by 
dissolving 10 mg of propranolol hydrochloride in 30 ml PBS pH 5.8 
followed by sonication for 10 min and volume was made upto 100 
ml using PBS pH5.8. The concentration of the standard stock 
solution was 100μg/ml. This was scanned between 400-200 nm. 
Drug compatibility with excipients 
The compatibility of drug with excipients is determined using FTIR 
spectral analysis [14]. 
Calibration curve of propranolol hydrochloride in PBS pH 5.8 
Dissolved 2.712g of potassium dihydrogen orthophosphate in 100 
ml distilled water and 0.8g of sodium hydroxide in 100 ml distilled 
water separately. From the prepared solution fixed volume of 
potassium dihydrogen orthophosphate and sodium hydroxide was 
taken into 100 ml standard flask and volume was made up to 200 ml 
mark using distilled water [15, 16]. 
Preparation of stock solution 
10 mg of propranolol hydrochloride in 30 ml phosphate buffer was 
sonicated for 10 min and the volume was made up to 100 ml mark 
using PBS pH 5.8 solution to get a concentration of 100μg/ml. 
Preparation of standard graph 
From the above solution, different concentrations were withdrawn 
and diluted to 10 ml with PBS pH 5.8 separately to prepare a series 
of concentrations from range 20-100μg/ml. The standard stock 
solution was scanned in the range of 400-200 nm against PBS pH 5.8 
as blank. Absorbance was plotted against concentration to obtain the 
standard graph. 
Formulation of propranolol hydrochloride topical gel 
Polymers carbapol 934 (0.15%w/v) and HPMC (0.25-0.30%w/v) in 
distilled water was taken in a glass beaker, soaked for 24 h [17]. 
Methanol was added to dissolve the drug. Then the drug was added 
to the above solution and made upto to the required quantity using 
remaining distilled water, which was then continuously stirred using 
a mechanical stirrer. The polymeric mixture with drug was 
neutralized using triethanolamine, followed by the addition of other 
ingredients like glycerine and ethylparaben with slow continuous 
stirring. Then the prepared formulation was transferred to collapsible 
tube and stored in a cool place. Prepared formulation was subjected to 
homogeneity study. Required quantity of the prepared gel was diluted 
with distilled water. The resulting solution, pH was determined, which 
was previously calibrated using PBS at pH 5.8 [18, 19]. 
Mean spreadability 
0.5 gm gel was pressed between two glass slides and then left for 
some time. The extent to which gel spreaded was determined [20]. 
Mean extrudability 
The gel formulations were filled into a collapsible metal tube or 
aluminium collapsible tube. The tube was pressed to extrude the 
material and the extrudability of the formulations was checked [21]. 
Mean drug content estimation 
Series of dilutions of the drug in methanol was made and transferred 
into 10 ml volumetric flask. The drug content was estimated on UV-
visible spectrophotometer at 289 nm using methanol as blank [22]. 
In vitro drug release study 
A soaked cellophane membrane was fixed on an open tube. In donor 
compartment, 1 gm of gel was taken and dipped in a 100 ml beaker 
containing drug-free PBS pH 5.8 (90 ml) as a receptor compartment 
and a temperature was maintained. Fixed volume of samples was 
taken at various intervals of time over a period of 7.5 h and the 
absorbances were recorded at 289 nm. The volume withdrawn at 
each time was replaced with drug-free PBS. The percentage of 
cumulative amount of drug released at various time intervals of time 
was calculated and plotted against time [23-25]. The kinetic models 
of in vitro drug release studies were plotted [26]. 
Ex vivo permeation comparison study 
The pigskin collected was fitted to the receptor compartment and 1 
gm of optimised gel (G2) containing 3 mg drug was taken in the cell 
and the cell was immersed in a beaker (100 ml) containing PBS pH 
5.8 (90 ml) as receptor compartment. The cell was dipped in 
between the 90 ml pH 5.8 [27, 28]. Fixed volume of sample was 
taken and determined the absorbance. Fresh PBS pH 5.8 solution 
was introduced at each withdrawal and the graph was plotted. 
Similarly the ex vivo permeation comparison study was done for the 
prepared topical propranolol hydrochloride solution, control drug 
solution (drug in PBS pH 5.8) by adding 1 ml each of formulation 
(containing 3 mg drug) in the donor compartment and the study was 
performed for a maximum period of 8 h [29, 30]. 
Steady-state flux determination 
From the above data steady-state flux (J) and enhancement ratio 
were found out [31, 32]. 
The steady-state values were then calculated from the slope value 
and was tabulated and statistical analysis by Student t-test was 
alsodone [33]. 
Histopathological examination 
The histopathological study was done for optimised propranolol 
hydrochloride topical gel (G2) formulation, topical propranolol 
hydrochloride solution, control drug solution (drug in PBS pH 5.8). 
The porcine skin was collected from the slaughterhouse and was 
proceeded to 6 h of ex vivo permeation study [34]. After 6 h, the skin 
mucosa was taken and immersed in 10% formalin solution and the 
preserved live tissues were equally cut into 5 µm containing sections 
and further stained with hemotoxylin and eosin and analysed using 
light microscope [35, 36]. 
Stability study 
The optimised topical Propranolol Hydrochloride gel formulation 
(G2) was subjected to stability studies [37]. 
RESULTS AND DISCUSSION 
Preformulation studies 
Fourier transform infrared (FTIR) spectroscopy  
FTIR spectrum of propranolol hydrochloride showed broad peak at 
3302.13 cm-1, indicating the presence of alcoholic OH group of 
propranolol hydrochloride. A characteristic peak at 2981 cm shows 
the presence of aromatic CH group. A peak at 2819.93 cm-1 
represents the presence of aliphatic CH. An absorption band in the 
range of 2031.04 cm-1 indicates the presence of C-C stretching of 
alkane. A peak at the range 1099.43 cm-1 represents C-O stretching. 
FTIR spectrum of carbapol 934 showed an absorption band in the 
region of 2956.87 cm-1 represents the presence of C-H stretching of 
alkane. A characteristic peak in the range of 1172.72 cm-1 indicates 
the presence of C-0 stretching. FTIR spectrum of HPMC showed a 
characteristic peak in the range of 2889.37 cm-1 represents the 
presence of C-H stretching of alkane. A peak at 1045.20 cm-1 
indicates the presence of C=0 functional group. FTIR spectrum of 
optimised topical propranolol hydrochloride gel formulation (G2) 
showed a broad peak at 3300.2 cm-1, indicating the presence of 
alcoholic O-H group of propranolol hydrochloride. A characteristic 
peak in the region of 2034.90 cm-1 indicates C-C stretching of alkane. 
A peak present in the range of 1597 cm-1 represents the presence of 
C=0 group. A characteristic peak in the range of 1099.43 cm-1 
indicates the presence of C-O stretching. No additional peaks were 
observed indicating good compatibility between drug and excipients 
when formulating it as a topical gel. The FTIR spectrum of the above 
compounds was shown in fig 1(A, B, C, D [38, 39]. 
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Fig. 1: (A) FTIR spectrum of Propranolol Hydrochloride, (B) FTIR spectrum of carbapol 934, (C) FTIR spectrum of HPMC, (D) FTIR 
spectrum of optimized propranolol hydrochloride topical gel 
 
Solubility study 
The pure drug was partially insoluble in chloroform and propylene 
glycol and soluble in distilled water, acetone, methanol Phosphate 
Buffer Saline (PBS) pH 5.8 [40]. 
Melting point 
The melting point of the drug ranges from 160-168 ⁰C [41, 42]. 
Lambda max of propranolol hydrochloride in phosphate buffer 
solution (PBS) pH 5.8 
The absorption maxima of propranolol hydrochloride in PBS pH 5.8 
was found to be 289 nm as shown in fig. 2(A) 
Calibration curve of propranolol hydrochloride in PBS pH 5.8 
The Standard calibration curve of drug was linear as shown in fig. 2(B) 
Formulation of propranolol hydrochloride topical gel 
The topical gel was formulated using the drug propranolol 
hydrochloride, which is the first-line agent for treating superficial 
Infantile Hemangioma and the polymer combination-carbapol 934 and 
Hydroxy Propyl Methyl Cellulose (HPMC) were also used [43, 44]. 0.15-
0.20% w/v of carbapol 934, a synthetic polymer was used in formulating 
topical gel, which possesses effective gelling property and HPMC, a 
semisynthetic polymer used in this formulation, also enhance the gelling 
property. Triethanolamine act as an acid neutralizer [45, 46]. Glycerine 
(5 ml) acts as a permeation enhancer for topical drug delivery. 
Ethylparaben acts as a preservative. The topical gel is shown in fig. 2(C). 
 
 
Fig. 2: (A) Lambda max of propranolol hydrochloride in PBS pH 5.8, (B) Calibration curve of propranolol hydrochloride, (C) Formulation 
of propranolol hydrochloride topical gel, (values are expressed as mean±standard deviation, n=3) 
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Characterization 
Characterisation of topical gel 
Homogeneity study 
All the prepared topical gels were uniform in appearance [47]. 
Mean surface pH 
The surface pH value ranges from 6.3±0.04 to 6.6±0.08, suitable for 
the topical application shown in fig. 3(C) [48]. 
Mean spreadability 
The spreadability of the topical gel formulation ranges from 
2.11±0.12gcm/min to 2.83±0.07 gcm/min and found to be suitable 
for the application shown in fig. 3(A) 
Mean extrudability 
The extrudability of the topical gels from the collapsible tube were 
also observed of which G2 formulation was easily extrudable when 
compared to the other formulation [49, 50]. 
 
 




Fig. 4: In vitro drug release study and its kinetic modelling (values are expressed as mean±standard deviation, n=3) 
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Mean drug content estimation 
Drug content values ranges from 85.27±0.23% to 94.21±0.41% for 
all the formulations. The drug content value was high in G2 
formulation shown in fig. 3(B) 
In vitro drug release study 
The in vitro drug release study of different gel formulations were 
carried out for 7.5 h in pH 5.8 solution [52]. pH 5.8 solution 
resembles the normal skin pH. Temperature was maintained. The 
cumulative percentage drug release of various gel formulations (G1-
G3) ranges from 88.90%±0.14 to 95.5%±0.15 at the end of 7.5 h. 
Selection of polymer is important in drug release study. The G2 gel 
showed highest cumulative percentage drug release that is, 
95.55%±0.15 at the end of 7.5 h. The drug release profile of topical 
propranolol hydrochloride gel with the highest drug release pattern, 
(G2) was attributed to various kinetic models. The drug release 
kinetics fitted to zero order as the R2 regression coefficient of the 
model was found to be 0.984 [53, 54]. This was best fitted with 
koresmeyer peppas plot (n=0.628) and follows non fickian diffusion 
were shown in fig. 4 
Ex vivo permeation comparison study 
The ex vivo permeation comparison study was carried out for 
optimised topical propranolol hydrochloride gel formulation (G2), 
topical Propranolol Hydrochloride solution and control drug solution 
(drug in PBS pH 5.8) by open-end tube method using normal pig skin 
[55, 56]. The pigskin was tied on one side of open end tube and 1 gm 
optimised topical propranolol hydrochloride gel formulation (G2) 
containing 3 mg drug was placed on top of the skin mucosa and 
carried out the ex vivo permeation study. Fixed volume of samples was 
taken and analysed [57, 58]. The result of ex vivo permeation study 
indicated that the optimised propranolol hydrochloride topical gel 
formulation (G2) showed maximum permeation (i.e. 2345µg/cm2) 
than topical propranolol hydrochloride solution (1001µg/cm2) and 
control drug solution (789.61µg/cm2) as shown in fig. 5 
 
 
Fig. 5: Ex vivo permeation comparison study, (values are expressed as mean±standard deviation, n=3) 
 
Table 1: Representation of flux, enhancement ratio parameters 
S. No. Parameters Optimised topical propranolol 
hydrochloride gel (G2) 
Topical propranolol 
hydrochloride solution  
 Control drug solution (drug 
in PBS pH 5.8) 
1 Steady state flux–J (μg/cm2/h) 4.61±0.31 1.97±0.22 1.67±0.35 
2 Enhancement ratio 2.8 1.1 - 
(Values are expressed as mean±standard deviation, n=3) 
 
The flux value obtained for optimised propranolol hydrochloride 
topical gel formulation (G2) was found to be 4.61μg/cm2/h. These 
values depicts that the optimised propranolol hydrochloride topical 
gel (G2) showed greater steady-state flux value 
(4.61±0.31µg/cm2/h) when compared to topical propranolol 
hydrochloride solution (1.97µg/cm2/h) and control drug solution 
(1.67µg/cm2/h). The enhancement ratio of optimised propranolol 
hydrochloride gel was found to be 2.8 and oral propranolol 
hydrochloride solution as 1.1 when compared with that of the 
control drug solution. The ex vivo permeation parameters confirmed 
that the permeation of propranolol hydrochloride across the pig skin 
layer was significantly higher when compared to topical propranolol 
hydrochloride solution and control drug solution which were shown 
in table 1 [59]. 
The statistical analysis by Student t-test was performed for the data 
obtained from the values of different formulations. The steady state 
flux value of the optimized topical propranolol hydrochloride gel 
formulation (G2) compared to the prepared topical propranolol 
hydrochloride solution and control drug solution. Hence the 
difference is statistically significant (P<0.05) as shown in fig. 5. 
Histopathological examination 
The pig skins subjected to 6 h permeation study were assessed for 
histopathological changes. The optimised topical propranolol 
hydrochloride gel formulation (G2), topical propranolol 
hydrochloride solution and control drug solution (drug in PBS pH 
5.8) showed no significant changes in the histological pattern when 
compared to normal skin tissue [60]. Hence, it was found that 
optimised topical propranolol hydrochloride gel does not cause any 
irritation and was found to be safe for topical application as shown 
in fig. 6. 
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(Scale bar = 35 µicrons with 10x magnifications) 
Fig. 6: Histopathological evaluation of pigskin treated with various formaulations, (A) Normal pig skin, (B) Pig skin treated with 
optimised topical propranolol hydrochloride (G2) gel formulation), (C) Pig skin treated with topical propranolol hydrochloride solution 
(D) Pigskin treated with control drug solution (drug in PBS pH 5.8) 
 
 
Fig. 7: (A) Stability study showing mean surface pH, (B) Mean drug content estimation, (C) Steady-state flux determination, (Values are 
expressed as mean±standard deviation, n=3) 
 
Stability study 
Parameters like pH and drug content were evaluated from 0 d to 45 
d at regular intervals in room temperature condition [61]. The 
optimised propranolol hydrochloride topical gel (G2) formulation 
was found to be stable at room temperature condition as shown in 
fig. 7(A, B) 
CONCLUSION 
Infantile Hemangioma (IH) is a benign vascular tumour of childhood 
characterized by endothelial cell proliferation. The main purpose of 
this study was to formulate a topical gel drug delivery system for 
treating IH that can bypass first-pass metabolism and nullify 
systemic side effects by delivering the drug directly in to the site of 
action. So by formulating the drug as topical gel, enhanced skin 
permeation was obtained. The steady-state flux were found to be 
higher for optimized topical propranolol hydrochloride gel 
formulation (G2) when compared to topical propranolol 
hydrochloride solution and control drug solution. Hence the 
formulated topical propranolol hydrochloride gel seems to be 
advantageous for enhanced skin delivery of first line agent 
propranolol hydrochloride for the treatment of Infantile 
Hemangioma, which could be further studied using suitable in vivo 
animal models. 
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